Discovery and Validation of a New Class of Small Molecule Toll-Like Receptor 4 (TLR4) Inhibitors

Many inflammatory diseases may be linked to pathologically elevated signaling via the receptor for lipopolysaccharide (LPS),\ud toll-like receptor 4 (TLR4). There has thus been great interest in the discovery of TLR4 inhibitors as potential antiinflammatory\ud agents. Recently, the structure of TLR4 bound to the inhibitor E5564 was solved, raising the possibility that\ud novel TLR4 inhibitors that target the E5564-binding domain could be designed. We utilized a similarity search algorithm in\ud conjunction with a limited screening approach of small molecule libraries to identify compounds that bind to the E5564 site\ud and inhibit TLR4. Our lead compound, C34, is a 2-acetamidopyranoside (MW 389) with the formula C17H27NO9, which\ud inhibited TLR4 in enterocytes and macrophages in vitro, and reduced systemic inflammation in mouse models of\ud endotoxemia and necrotizing enterocolitis. Molecular docking of C34 to the hydrophobic internal pocket of the TLR4 coreceptor\ud MD-2 demonstrated a tight fit, embedding the pyran ring deep inside the pocket. Strikingly, C34 inhibited LPS\ud signaling ex-vivo in human ileum that was resected from infants with necrotizing enterocolitis. These findings identify C34\ud and the b-anomeric cyclohexyl analog C35 as novel leads for small molecule TLR4 inhibitors that have potential therapeutic\ud benefit for TLR4-mediated inflammatory diseases